Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 3,500 shares, an increase of 169.2% from the May 15th total of 1,300 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.0% of the shares of the company are short sold.
Pharming Group Price Performance
Shares of NASDAQ PHAR traded up $0.55 during trading hours on Monday, hitting $11.30. 5,054 shares of the stock were exchanged, compared to its average volume of 6,233. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a market cap of $768.55 million, a PE ratio of -43.45 and a beta of 0.02. The company's fifty day simple moving average is $9.70 and its two-hundred day simple moving average is $9.20. Pharming Group has a 1-year low of $6.65 and a 1-year high of $12.61.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The business had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. On average, sell-side analysts predict that Pharming Group will post -0.2 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Oppenheimer increased their target price on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.
Read Our Latest Analysis on PHAR
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.